The Health Policy Partnership

What The Health Policy Partnership does

The Health Policy Partnership (HPP) is a London-based specialist health policy consultancy founded in 2014 that helps clients translate evidence into policy change. Operating with a headcount of 33 and headquartered at 68–69 St Martin's Lane, HPP serves pharmaceutical and life sciences companies, healthcare industry associations, government health authorities, and patient advocacy organisations by conducting policy research, synthesising complex datasets, and convening stakeholders around shared objectives. Its delivery model rests on three explicit pillars: research (distilling data into compelling narratives), people (building multi-stakeholder alliances), and action (creating resources that drive advocacy and policy reform).

HPP's most differentiated analytical asset is the Radioligand Therapy Readiness Assessment Framework, a proprietary five-domain tool covering governance, regulation and reimbursement, identified need, service provision, and health information. The framework has been adapted for the UK, US, Malaysia, Saudi Arabia, Taiwan, and UAE, and is published under Creative Commons licensing. HPP also serves as Secretariat for international multi-stakeholder networks including the Lung Cancer Policy Network and the Heart Failure Policy Network, which function as ongoing convening platforms for global policy activity in oncology and cardiovascular care. Beyond radioligand therapy, the firm publishes policy briefs and reports on cancer care, cardiovascular disease, vaccination, and pharmaceutical R&D innovation, including a 2025 brief developed with the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).

HPP operates a professional services and project-funded commercial model. Revenue is generated through commissioned research and policy projects paid for by pharmaceutical companies (Roche, Novartis, Sanofi, Boehringer Ingelheim, Janssen, UCB, Siemens Healthineers and others), industry associations (IFPMA, EHMA, All.Can), and foundations. Geographic delivery spans the UK, Ireland, continental Europe, the United States, Malaysia, Saudi Arabia, Taiwan, the UAE, South Africa, Australia, Mexico, and the broader MENA region. Distribution occurs through direct enterprise engagement, public dissemination of research outputs, and ongoing leadership of the multi-stakeholder networks that the firm has initiated.

Name

The Health Policy Partnership

Legal name

The Health Policy Partnership Ltd

Website

https://healthpolicypartnership.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

The Health Policy Partnership is a London-based specialist health policy consultancy that translates evidence into policy change for pharmaceutical companies, industry associations, governments, and patient groups through research, multi-stakeholder alliance building, and proprietary readiness frameworks.

Ownership category

akta.pro rank

Product category

Health Policy Consulting

NAICS

Social Assistance (624)

SIC

Services-Misc Health & Allied Services, Nec (8090), Services-Membership Organizations (8600)

akta.pro primary industry

Public Health Strategy, Policy & Legislation (HLAJAMAA)

akta.pro secondary industries

Public–Private Partnerships (PPPs) for Global Health (HLAJAOAD), Global Health Research, Evidence & Technical Assistance Organizations (HLAJAKAN)

Keywords

• Health policy consulting
• Policy research services
• Stakeholder alliance building
• Health system readiness
• Policy advocacy resources

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Consultancy Services: HPP provides specialist health policy consultancy services including research, writing, editing and communications. Clients commission HPP for projects to help inform policymakers about key health issues.
2. Project Funding: HPP receives project funding from pharmaceutical companies, industry associations, and foundations to conduct health policy research and develop frameworks, reports and advocacy resources.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

The Health Policy Partnership is a specialist health policy consultancy that delivers commissioned research, analysis, writing, editing, and communications work for clients in the pharmaceutical, life sciences, healthcare association, and government sectors. It distils complex data into evidence-based narratives, convenes and leads international multi-stakeholder alliances, and creates frameworks, reports, and advocacy resources—such as the Radioligand Therapy Readiness Assessment Framework and Patient Advocacy Toolkit—designed to catalyse health system change and improve patient access to innovative therapies.

Product overview

The Health Policy Partnership is a specialist health policy consultancy that catalyses health system change through three core capabilities: research (distilling complex data into narratives), people (building alliances of stakeholders), and action (creating resources for advocacy). The company offers specialized frameworks and toolkits for health system readiness assessment, including the Radioligand Therapy Readiness Assessment Framework and its associated Readiness Hub and Patient Advocacy Toolkit, alongside policy reports and publications addressing cancer care, cardiovascular health, and R&D innovation. HPP also acts as Secretariat for multi-stakeholder networks including the Heart Failure Policy Network and Lung Cancer Policy Network.

Differentiator

Problem solved

Functional benefit

Products and services

• Radioligand Therapy Readiness Assessment Framework An international framework to assess health system readiness for radioligand therapy, dividing the health system into five domains: governance, regulation and reimbursement, identified need, service provision and health information. Available under Creative Commons licensing and intended for policymakers and health system stakeholders worldwide.
• Radioligand Therapy Readiness Hub An online resource collecting examples that highlight different ways of improving the integration of radioligand therapy into cancer care and boosting readiness for the approach in the future.
• Radiopharmaceuticals Patient Advocacy Toolkit An online resource for patient advocates to learn more about radiopharmaceutical diagnostics and treatments and how to advocate for equitable access to them.
• Radioligand Therapy Policy Report A policy report raising awareness of radioligand therapy as an innovative component of cancer care, developed with a multi-stakeholder steering committee through desk research and expert interviews.
• Advanced Cancer Therapies in Ireland Report A policy-focused narrative with actionable recommendations to improve access to advanced cancer therapies in Ireland, launched at the All-Island Cancer Summit.
• Enabling Innovation: The R&D Ecosystem for Medicines and Vaccines A policy brief developed with IFPMA examining how the R&D ecosystem for medicines and vaccines is evolving, where pressures and bottlenecks arise, and how policy choices will shape the future of innovation and access.

Quantifiable outcome

• Gavi, which HPP uses as an example of successful alliance-building, has helped vaccinate over 900 million children worldwide, saving an estimated 11 million lives.

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core, minor and major.

• InbeeocoreStrategic or Co-development Partner · 14 May 2026HPP partnered with Inbeeo, a consultancy specializing in market access and pricing strategy for life science and medical technology companies. The partnership combines HPP's health policy expertise with Inbeeo's market access insights, offering clients integrated solutions at the intersection of policy, system shaping, and market access. HPP CEO Jody Tate noted the partnership will allow clients to build on policy work while driving effective implementation through market access strategy.
• Atlas Clarity LLCminorStrategic or Co-development Partner · 29 April 2026HPP collaborated with Atlas Clarity on a blog post about vaccination gaps and equity issues, examining lessons from London and San Francisco in reaching underserved populations with immunisation programmes.
• Vista HealthminorStrategic or Co-development Partner · 1 January 2026HPP announced a strategic partnership with Asia health policy experts Vista Health to strengthen regional policy work in the Asia-Pacific region.
• International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)majorStrategic or Co-development Partner · 23 September 2025HPP worked with IFPMA to develop a policy brief examining how the R&D ecosystem for medicines and vaccines is evolving, where pressures and bottlenecks arise, and how policy choices will shape future innovation and access. The brief was developed closely with IFPMA's Research & Development and Innovation Committee.
• European Health Management Association (EHMA)minorStrategic or Co-development Partner · 1 January 2023HPP partnered with EHMA to develop a report on health system readiness for innovation, outlining principles required for effective implementation of innovations and highlighting how frameworks can be used to achieve this.
• Asia Pacific Coalition against Lung Cancer (a clinical expert group)minorStrategic or Co-development Partner · 1 January 2023The Lung Cancer Policy Network partnered with the Asia Pacific Coalition against Lung Cancer to facilitate bidirectional policy change and shared learning on lung cancer screening, with the Network providing a global arena for shared learning and delivering global policy recommendations.
• ASPIRE for Lung CancerminorStrategic or Co-development Partner · 1 January 2023The Lung Cancer Policy Network partnered with ASPIRE for Lung Cancer to support regional lung cancer policy efforts, ensuring best practices from global developments are brought to APAC health systems while regional experiences inform global balance.
• Nordic NanovectorminorStrategic or Co-development Partner · 1 January 2023Nordic Nanovector provided additional support for specific outputs in HPP's radioligand therapy work.
• Advanced Accelerator Applications (AAA), a Novartis CompanymajorStrategic or Co-development Partner · 1 January 2020AAA, a Novartis company, provided funding and support for the development of the Radioligand Therapy Readiness Assessment Framework and related policy work. The framework was launched at ASCO Conference and expanded to include work on national calls to action in multiple countries.
• CuriumminorStrategic or Co-development Partner · 1 January 2020Curium provided additional support for specific outputs in HPP's radioligand therapy project.
• NovartismajorStrategic or Co-development Partner · 1 January 2019Novartis supported HPP's radioligand therapy work including the international framework development, national calls to action projects in Malaysia, Saudi Arabia, Taiwan, and UAE, and the advanced cancer therapies project in Ireland. HPP maintains full editorial control of all outputs.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Global Health Strategies: Global Health Strategies is a health-focused communications and policy consultancy that supports governments, NGOs, and industry on advocacy and policy change. It mirrors HPP's alliance-building and policy narrative work across global health priorities.
• Avalere Health: Avalere Health is a US-based health policy, strategy, and evidence consultancy serving pharma, providers, and government. It is a direct peer to HPP in health policy research, stakeholder convening, and frameworks for health system change.
• The Lewin Group: The Lewin Group is a US health policy and human services consultancy delivering evidence-based analysis to government and industry. Comparable to HPP in policy research depth and government-facing advisory work.
• Putnam Associates: Putnam Associates is a life sciences strategy consultancy with a strong focus on market access, pricing, and policy shaping for pharma clients. Comparable to HPP in serving pharma strategy and access teams on policy-driven evidence work.
• Rabin Martin: Rabin Martin is a health-focused strategy and policy firm helping life sciences clients navigate access, advocacy, and stakeholder engagement. Comparable to HPP in mission, client base, and emphasis on convening across the health ecosystem.

Emerging players

• Policy Analysis Inc. Policy Analysis Inc. is a smaller US-based health and social policy consultancy providing research and analytical services to federal and state agencies. It is an emerging specialist peer with overlapping policy research capabilities, though primarily US-focused.

Broad incumbents

• IQVIA (Consulting Services): IQVIA is the largest life sciences and healthcare data and consulting firm globally, offering policy, evidence, and market access services. It is a broad incumbent competing for the same pharma evidence and policy shaping engagements as HPP.
• Charles River Associates (Healthcare Practice): Charles River Associates is a global consultancy with a dedicated healthcare practice covering life sciences, payer, and provider strategy. It competes for similar pharma policy and evidence mandates but at a much larger scale and broader portfolio.
• FTI Consulting (Healthcare & Life Sciences): FTI Consulting is a global advisory firm with a healthcare and life sciences segment covering policy, communications, and stakeholder strategy. It competes for the same pharma and association clients as HPP on policy shaping mandates.

Others

• McKinsey (Health Practice): McKinsey's global health practice advises governments and life sciences companies on health system performance and innovation. It is a broad incumbent that occasionally competes with specialist policy shops like HPP on access and innovation mandates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/radioligand
• LinkedInlinkedin.com/company/the-health-policy-partnership

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Health Policy Partnership